证券代码：688293 证券简称：奥浦迈 公告编号：2026-025 上海奥浦迈生物科技股份有限公司 关于完成注册资本变更登记、修订《公司章程》并换 发营业执照的公告 统一社会信用代码：91310115084100518T 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 关于上海奥浦迈生物科技股份有限公司（以下简称"公司"）通过发行股份 及支付现金方式购买澎立生物医药技术（上海）股份有限公司100.00%股权，并 向不超过35名特定投资者发行股票募集配套资金（以下简称"本次交易"）事项， 已于2025年12月31日获得中国证券监督管理委员会同意注册批复。 公司分别于2025年6月4日、2025年6月23日、2026年1月29日召开第二届董事 会第十次会议、2025年第一次临时股东大会和第二届董事会第十九次会议，审议 通过了《关于提请股东大会授权董事会及其授权人士全权办理本次交易相关事宜 的议案》《关于提请董事会授权董事长全权办理本次交易相关事宜的议案》。具 体内容详见公司分别于2025年6月6日、2025年6月24日、20 ...

上海奥浦迈生物科技股份有限公司 章程 二〇二六年三月 1 | 目录 | | --- | | 第一章 | 总则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股份 | 6 | | 第一节 | 股份发行 6 | | | 第二节 | 股份增减和回购 7 | | | 第三节 | 股份转让 8 | | | 第四章 | 股东和股东会 | 9 | | 第一节 | 股东 9 | | | 第二节 | 股东会的一般规定 14 | | | 第三节 | 股东会的召集 18 | | | 第四节 | 股东会的提案与通知 19 | | | 第五节 | 股东会的召开 21 | | | 第六节 | 股东会的表决和决议 24 | | | 第五章 | 董事会 | 29 | | 第一节 | 董事 29 | | | 第二节 | 董事会 35 | | | 第三节 | 董事会专门委员会 41 | | | 第六章 | 高级管理人员 | 43 | | 第七章 | 财务会计制度、利润分配和审计 | 45 | | 第一节 | 财务会计制度 45 | | | 第二节 | 内部审计 52 | | | ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a core engine of economic growth [16][17]. - As of March 6, 2026, the total value of business development (BD) contracts for Chinese innovative drugs has reached $56.8 billion, with an upfront payment of $3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamentals of quality companies remain solid, and the long-term growth logic for innovative drug exports is still intact [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baiyue Tianheng [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies top-performing stocks for the week, including Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%), while highlighting significant declines in stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) [9].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The clinical research organization (CRO) sector is experiencing a significant recovery, with new orders and backlog orders showing rapid growth. Notable companies like Medpace and Yino Science have reported substantial increases in new orders and revenue [4][14] - The price of experimental monkeys, a key material for preclinical research, has surged, indicating strong demand in the domestic innovative drug industry. The price has risen to over 130,000 yuan per monkey, up from approximately 90,000 yuan in mid-2025 [5][15] - The report emphasizes the continued recommendation of the domestic preclinical CRO sector, anticipating further acceleration in order growth [5][14] Summary by Sections Section 1: Order Growth in Preclinical CRO - Medpace signed new orders worth approximately 1.6 billion yuan in 2025, a year-on-year increase of about 45%, with revenue also growing by 12% [14][15] - Yino Science reported new orders of 1.135 billion yuan, up 38.62% year-on-year, with a backlog of 1.248 billion yuan, reflecting a 28.23% increase [14][15] - The backlog for Aopumai's subsidiary, Pengli Biology, reached 252 million yuan, a 37.68% increase year-on-year [14][15] Section 2: Market Performance - In the first week of March 2026, the pharmaceutical and biological sector fell by 2.78%, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th among 31 sub-industries [6][17] - The in vitro diagnostics sector showed the highest increase, while the medical research outsourcing sector experienced the largest decline, down 4.99% [20][21] Section 3: Recommendations - The report maintains a positive outlook on the innovative drug and its supply chain, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [7] - Monthly recommendations include companies such as WuXi AppTec, CSPC Pharmaceutical Group, and Innovent Biologics, while weekly recommendations feature Aopumai, Medpace, and others [7]

证券代码：688293 证券简称：奥浦迈 公告编号：2026-024 上海奥浦迈生物科技股份有限公司 关于开设本次向特定对象发行A股股票募集资金专项 账户并授权签署监管协议的公告 | | 项目名称 | 拟使用募集资金金额 （万元） | 使用金额占全部募集配套资 金金额的比例 | | --- | --- | --- | --- | | 募集配套资 | 支付本次交易现金 对价及税费 | 34,726.36 | 95.92% | | 金用途 | | | | | | 支付中介机构费用 | 1,478.63 | 4.08% | | | 合计 | 36,204.99 | 100% | 为规范公司募集资金的存放、管理与实际使用，保护投资者权益，根据《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》以及公司《募集资金管理办法》等相关规定，董事会同意公司 在相关商业银行开设募集资金专项账户，用于本次募集配套资金的管理与使用。 同时，公司董事会授权董事长及其授权人士全权办理本次募集配套资金涉及 的募集资金专用账户开立事宜，包括但不限于办理开户手续、与独立财务顾问以 及存放本次募集配套 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2026-023 上海奥浦迈生物科技股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 根据中国证券监督管理委员会出具的《关于同意上海奥浦迈生物科技股份有 限公司发行股份购买资产并募集配套资金注册的批复》（证监许可〔2025〕3036 号），同意公司通过发行股份及支付现金方式购买澎立生物医药技术（上海）股 份有限公司100.00%股权（以下简称"本次发行股份及支付现金购买资产"）， 并向不超过35名特定投资者发行股票募集配套资金（以下简称"本次募集配套资 金"，与本次发行股份及支付现金购买资产合称"本次交易"）。本次拟募集配 套资金金额不超过36,204.99万元，主要用于支付本次交易现金对价及税费、支付 中介机构费用。 为规范公司募集资金的存放、管理与实际使用，保护投资者权益，根据《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1 号——规范运作》以及公司《募集资金管理办法》等 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

中证智能财讯奥浦迈（688293）2月27日晚间披露2025年业绩快报，公司实现营业收入3.55亿元，同比增长19.4%；归母净利润4169.85万元，同比增长 98.07%；扣非净利润2084.9万元，同比增长216.57%；基本每股收益0.37元，加权平均净资产收益率为1.99%。以2月27日收盘价计算，奥浦迈目前市盈率 （TTM）约为158.79倍，市净率（LF）约2.53倍，市销率（TTM）约18.76倍。 以本次披露业绩快报数据计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 400 超00 200 202 112.72 100 96:73 82.2 de -63:04 7261 52.46 0 -100 -200 -300 2024-03-30 023-09-30 ' -06-30 <3-12-30 ' 24-06-30 4-12-30 2n. -○- 公司 -○- 行业均值 100 ହ 90 86.31 80 70 62.14 60 50 47-98 48.81 40 30 240 20 12 98 10 3.84 0 2023-06-30 I 2023-12-30 ' 2 ...

格隆汇2月27日丨奥浦迈(688293.SH)公布，为确保公司董事会的规范运作，公司于同日召开职工代表大 会，经与会职工代表充分讨论，取得一致意见，同意选举贾丰彬先生担任公司第二届董事会职工代表董 事，任期自本次职工代表大会审议通过之日起至第二届董事会任期届满之日止。 ...

格隆汇2月27日丨奥浦迈(688293.SH)公布2025年度业绩快报，2025年，公司实现营业收入3.55亿元，相 较上年同期增加19.40%；实现归属于母公司所有者的净利润为4169.85万元，相较上年同期增加 98.07%；实现归属于母公司所有者扣除非经常性损益后的净利润为2084.90万元，相较上年同期增加 216.57%。 报告期内，公司产品业务板块实现销售收入23.03%的增长，展现出强劲且稳健的发展势头。这主要得 益于公司在重点客户管线上的持续深化及向后推进、市场开拓力度的不断扩大，以及产品核心竞争力的 持续提升，为该业务的持续增长奠定了坚实基础。 ...